Mallinckrodt Divests to Pursue Specialty Pharma Niche

by | Jan 31, 2017 7:20 pm | Pharmaceuticals

The latest watchword for the pharmaceutical industry is “specialization,” as in “specialization is a safer bet than diversification.” A lot of big-name pharma companies are divesting their non-core businesses in order to target specific therapeutics and disease areas. The most recent example is Mallinckrodt plc (NYSE:MNK), which has sold off approximately $893 million of its assets in the past six months, in order to focus on its specialty pharmaceutical platforms in autoimmune and rare diseases. In August 2016, Mallinckrodt sold its nuclear imaging business for $690 million to IBA Molecular, a global manufacturer and distributor of... Read More »